Search research articles
Contact Us
Filters
Showing results (61-70 of 75) with videos related to
Page
of 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2019
FOLFOXIRI Plus Panitumumab As First-Line Treatment of <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)
Dominik P Modest, Uwe M Martens, Jorge Riera-Knorrenschild, et al.
JAMA Oncology
|
June 26, 2020
Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial
Javier Cortés, Véronique Diéras, Sylvie Lorenzen, et al.
Cancers
|
April 27, 2024
NGS-Guided Precision Oncology in Breast Cancer and Gynecological Tumors-A Retrospective Molecular Tumor Board Analysis
Niklas Gremke, Fiona R Rodepeter, Julia Teply-Szymanski, et al.
BMC Cancer
|
March 1, 2020
High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08
Martin Fehr, Hanne Hawle, Stefanie Hayoz, et al.
International Journal of Cancer
|
April 28, 2020
Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)
Sylvie Lorenzen, Jorge Riera Knorrenschild, Claudia Pauligk, et al.
Nature Communications
|
February 27, 2026
First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial
Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C Thuss-Patience, et al.
Nature Communications
|
April 17, 2026
Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial
Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C Thuss-Patience, et al.
Cancer Immunology Research
|
November 11, 2024
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
Joseph Tintelnot, Lisa Paschold, Eray Goekkurt, et al.
JAMA Oncology
|
June 23, 2022
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial
Alexander Stein, Lisa Paschold, Joseph Tintelnot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2023
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial
Sylvie Lorenzen, Thorsten Oliver Götze, Peter Thuss-Patience, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 75) with videos related to
Sort By:
Page
of 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2019
FOLFOXIRI Plus Panitumumab As First-Line Treatment of <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)
Dominik P Modest, Uwe M Martens, Jorge Riera-Knorrenschild, et al.
JAMA Oncology
|
June 26, 2020
Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial
Javier Cortés, Véronique Diéras, Sylvie Lorenzen, et al.
Cancers
|
April 27, 2024
NGS-Guided Precision Oncology in Breast Cancer and Gynecological Tumors-A Retrospective Molecular Tumor Board Analysis
Niklas Gremke, Fiona R Rodepeter, Julia Teply-Szymanski, et al.
BMC Cancer
|
March 1, 2020
High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08
Martin Fehr, Hanne Hawle, Stefanie Hayoz, et al.
International Journal of Cancer
|
April 28, 2020
Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)
Sylvie Lorenzen, Jorge Riera Knorrenschild, Claudia Pauligk, et al.
Nature Communications
|
February 27, 2026
First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial
Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C Thuss-Patience, et al.
Nature Communications
|
April 17, 2026
Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial
Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C Thuss-Patience, et al.
Cancer Immunology Research
|
November 11, 2024
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
Joseph Tintelnot, Lisa Paschold, Eray Goekkurt, et al.
JAMA Oncology
|
June 23, 2022
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial
Alexander Stein, Lisa Paschold, Joseph Tintelnot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2023
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial
Sylvie Lorenzen, Thorsten Oliver Götze, Peter Thuss-Patience, et al.
Page
of 8